Picture of Ventyx Biosciences logo

VTYX — Ventyx Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Ventyx Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary

* Ventyx Biosciences Inc  VTYX.OQ  reported a quarterly
adjusted
loss of 50 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -92 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 52 cents per
share. Wall Street expected results to range from -62 cents
to -43 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Ventyx Biosciences Inc's reported EPS for the quarter was
a loss
of 50 cents​.
    * The company reported a quarterly loss of $35.25 million.
    * Ventyx Biosciences Inc shares had risen by 6.9% this
quarter and
lost 5.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ventyx
Biosciences Inc is $10.00 
This summary was machine generated from LSEG data November 8 at
04:20 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.52          -0.50          Beat
 Jun. 30 2024      -0.58          -0.45          Beat
 Mar. 31 2024      -0.69          -0.62          Beat
 Dec. 31 2023      -0.90          -0.79          Beat

Recent news on Ventyx Biosciences

See all news